For this proof-of-concept study, we chose dacarbazin, an alkylating chemotherapeutic agent approved for the first-line treatment of metastatic UM patients, and everolimus, an mTOR inhibitor that is currently being approved for the treatment of certain types of renal, pancreatic, and breast cancers and that had previously showed some efficacy in UM PDXs [28]. The gene discussed is MTOR; the disease is breast carcinoma.